Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4

Documenti analoghi

• Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial
  di: Massimo Nardone, et al.
  Pubblicazione: (2026)
• Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial
  di: Amrit Pathak, et al.
  Pubblicazione: (2025)
• Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
  di: Vikas S. Sridhar, et al.
  Pubblicazione: (2024)
• Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
  di: Ayodele Odutayo, et al.
  Pubblicazione: (2024)
• Biomarkers for cardiovascular–kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment
  di: Kevin Yau, et al.
  Pubblicazione: (2025)